1. According to the World Health Organization and the World Symposium on Pulmonary Hypertension, pulmonary arterial hypertension is classified as which form of pulmonary hypertension?
A. Group 1
B. Group 2
C. Group 3
D. Group 4
2. Which of the following World Health Organization (WHO) functional classes is correctly matched with its definition?
A. WHO functional class I – slight limitation in physical activity
B. WHO functional class II – inability to carry out physical activity
C. WHO functional class III – marked limitation in physical activity
D. WHO functional class IV – no limitations in physical activity
3. For which of the following medications does the Food and Drug Administration require a Risk Evaluation and Mitigation Strategies program due to its risk of hepatotoxicity?
A. Ambrisentan
B. Bosentan
C. Riociguat
D. Macitentan
4. Which of the following medications works on the nitric oxide pathway to improve symptoms of pulmonary arterial hypertension?
A. Selexipag
B. Bosentan
C. Riociguat
D. Treprostinil
5. Which of the following endothelin receptor antagonists does not have any unique major drug interactions and is thought to be the most well-tolerated agent in the class?
A. Bosentan
B. Ambrisentan
C. Macitentan
D. Riociguat
6. Which of the following medications is dosed up to 9 times daily as an inhaled solution?
A. Sildenafil
B. Selexipag
C. Iloprost
D. Macitentan
7. Which of the following is true about treprostinil?
A. Addition of oral treprostinil as a second-line agent has been shown to be ineffective
B. Intravenous infusions of treprostinil should be administered over the course of 1 hour every 2 weeks
C. Abrupt discontinuation of treprostinil helps avoid the withdrawal effects seen with a gradual taper
D. Inhaled treprostinil should initially be prescribed as 1 inhalation twice daily
8. Combination therapy with riociguat and which of the following medications should be avoided?
A. Sildenafil
B. Ambrisentan
C. Selexipag
D. Treprostinil
9. The Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial showed which of the following therapeutic approaches to be more effective for improving time to first event of clinical failure?
A. Initial combination therapy compared to ambrisentan or tadalafil alone
B. The use of either tadalafil or ambrisentan compared to placebo
C. Sequential add-on of tadalafil to ambrisentan compared to ambrisentan alone
D. Sequential add-on of ambrisentan to tadalafil compared to tadalafil alone
10. Which of the following medications is the most evidence-based agent for monotherapy in patients with World Health Organization functional class IV pulmonary arterial hypertension?
A. Sildenafil
B. Epoprostenol
C. Riociguat
D. Bosentan
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. To what extent did the program meet objective #5?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
23. Will the information presented cause you to change your practice?
A. Yes
B. No
24. Are you committed to making these changes?
A. Yes
B. No
25. As a result of this activity, did you learn something new?
A. Yes
B. No
26. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
27. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20
